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Fabry disease is a lysosomal storage disorder caused by 
a deficiency of α-galactosidase A (α-gal A) activity that 
results in progressive globotriaosylceramide (Gb3) depo-
sition. We created a fully congenic nonobese diabetic 
(NOD)/severe combined immunodeficiency (SCID)/
Fabry murine line to facilitate the in vivo assessment of 
human cell-directed therapies for Fabry disease. This pure 
line was generated after 11 generations of backcrosses 
and was found, as expected, to have a reduced immune 
compartment and background α-gal A activity. Next, 
we transplanted normal human CD34+ cells transduced 
with a control (lentiviral vector-enhanced green fluores-
cent protein (LV-eGFP)) or a therapeutic bicistronic LV 
(LV-α-gal A/internal ribosome entry site (IRES)/hCD25). 
While both experimental groups showed similar engraft-
ment levels, only the therapeutic group displayed a 
significant increase in plasma α-gal A activity. Gb3 quan-
tification at 12 weeks revealed metabolic correction in 
the spleen, lung, and liver for both groups. Importantly, 
only in the therapeutically-transduced cohort was a sig-
nificant Gb3 reduction found in the heart and kidney, 
key target organs for the amelioration of Fabry disease 
in humans.
Received 13 July 2011; accepted 6 March 2012;advance online 
publication 3 April 2012. doi:10.1038/mt.2012.64
IntroductIon
Fabry disease is an X-linked lysosomal storage disorder caused by 
a deficiency in the hydrolase, α-galactosidase A (α-gal A), which 
catalyzes the cleavage of the terminal molecule of galactose from 
neutral glycosphingolipids. The main consequence of this meta-
bolic anomaly is a progressive lipid accumulation throughout the 
body, particularly involving globotriaosylceramide (Gb3).
1 The 
accumulation of Gb3 in endothelial cells from the kidneys, heart, 
and brain leads to life-threatening complications and early death. 
Compared to the normal population, Fabry patient life expec-
tancy is reduced 15 and 20 years for heterozygous women and 
hemizygous men, respectively, with a steep decline in survival 
after 35 years of age.2,3 Enzyme replacement therapy (ERT) has 
now been commercially available as specific treatment for Fabry 
disease for almost 10 years. During this period, several clinical 
trials have shown some positive effects from ERT in treating pain, 
reducing heart size, stabilizing kidney function, and improving 
hearing and sweating.4,5 However, this therapy is hampered by 
both economic (~250,000 USD/patient/year) and therapeutic 
(variable clinical efficacy) considerations.6,7 Furthermore, it has 
been demonstrated that ERT is effective for stabilizing renal func-
tion and reducing left ventricular wall thickness, two of the major 
clinical concerns on Fabry disease, only when it is provided at an 
early phase of the disease.8–11 Moreover, ERT constitutes only a 
short-term treatment, given the limited half-life of the enzyme 
product in vivo, and does not solve the underlying genetic defect 
of this disorder.
Fabry disease is a natural candidate for gene therapy. α-Gal 
A can diffuse from engineered cells and be subsequently taken 
up by bystander deficient cells through mannose 6-phosphate 
receptor–mediated salvage pathway in a process called meta-
bolic cooperativity.12,13 Previously, we demonstrated that by 
using genetically modified murine bone marrow cells it is pos-
sible to attain long-term enzymatic correction and Gb3 reduc-
tion in primary and secondary transplanted Fabry mice.14 By 
using different integrating viral vectors we were able to signifi-
cantly increase the α-gal A activity of mobilized Fabry patient 
hematopoietic stem cells (HSCs).15,16 Here, we aimed to generate 
a more suitable Fabry mouse model that would allow us to better 
close the conceptual gap between the bench and the clinic. We 
also sought to affirm the advantages of metabolic cooperativity 
as directed towards relevant organs in the management of the 
disorder.
In this report, we describe a novel pure murine nonobese dia-
betic (NOD)/severe combined immunodeficiency (SCID)/Fabry 
line that supports human hematopoiesis. Furthermore, we demon-
strate that the metabolic cooperativity effect led to reduced levels 
of Gb3 in key organs over human HSC transplantation alone. This 
study provides crucial preclinical data for a Fabry gene therapy 
trial and validates this model for gauging the effectiveness of novel 
human cell-based therapies for Fabry disease.
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results
characterization of nod/scId/Fabry mice
Eleven backcrossings were performed starting from parental 
female-Fabry mice17 and male-NOD/SCID mice. Throughout the 
breeding program, we performed an exhaustive analysis of the 
genotype (Fabry and NOD/SCID) and phenotype (deficient α-gal 
A enzyme activity in plasma; absence of T and B cells in peripheral 
blood (PB)) of the females in order to select the optimal breeders 
for the next generation and to ensure that genetic drift or “leaki-
ness” of the mutations had not occurred (data not shown). Fabry-
carrier homozygous NOD/SCID females were obtained at the 
third generation (F3). As expected, the NOD/SCID genetic back-
ground content of the F11-mice was >99% (data not shown), dem-
onstrating that the new NOD/SCID/Fabry (NSF) line was fully 
congenic. The absence of T and B cells in the PB, as well as the 
lack of α-gal A activity in plasma confirmed the NSF phenotype 
of this novel line (Figure 1a,b). The α-gal A deficiency was also 
evident in the heart, kidney, spleen, liver, and lung (Figure 1c), 
which contributed to a significant accumulation of Gb3 in the same 
organs (Figure 1d). Importantly, we found that all the biochemi-
cal parameters analyzed in this new model were comparable to 
results from the preexisting Fabry mouse (Figure 1b–d). Finally, 
F11-mice were intercrossed and subsequently all the F13-females 
and -males were homozygous or hemizygous for the Fabry geno-
type, respectively.
High levels of α-gal A activity in vitro achieved by 
lentiviral vector-mediated gene transfer into human 
hematopoietic cells
We have previously demonstrated that Gb3 accumulation in  tissues 
was completely prevented by neonatal injections of a recombinant 
lentiviral vector (LV) carrying the wild-type α-gal A cDNA as 
well as the selectable marker hCD25 cDNA (LV-α-gal A/inter-
nal ribosome entry site (IRES)/hCD25).16 Here, using the same 
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Figure 1 Phenotypic characterization of the novel nod/scId/Fabry xenograft model. Eleven generations of backcrossings were performed to 
generate a fully congenic NOD/SCID/Fabry line. At each generation different phenotypic studies were performed. (a) Representative flow cytometry 
analysis of the percentage of T and B cells in peripheral blood. Different F11-individuals were compared with the parental mouse lines. (b) Plasma α-gal A 
enzyme activity was analyzed for the new mouse line and also compared to an earlier Fabry mouse model. (c) Specific enzyme activity in different organs. 
(d) Gb3 quantification by HPLC. Data represent mean ± SD from five individuals (F11) per group. *P < 0.001 compared to wild-type control groups. α-gal 
A, α-galactosidase A; BL6, wild-type; Fabry, traditional Fabry mice; FITC, fluorescein isothiocyanate; Gb3, globotriaosylceramide; HPLC, high- performance 
liquid chromatography; NOD, nonobese diabetic; NSF, NOD/SCID/Fabry; NS, NOD/SCID; SCID, severe combined immunodeficiency.
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vector (Figure 2) we transduced human cells including: K562 
cells, Fabry patient B cells, and HSCs, and tested the therapeutic 
potential of this vector in vitro. We found that with a multiplicity 
of infection as low as 10, it was possible to modify ~70% and ~40% 
of the K562 cells (Supplementary Figure S1a) and Fabry patient 
B cells (Supplementary Figure S1c), respectively. Concomitantly, 
the intracellular α-gal A specific activity was increased more 
than tenfold and fourfold, respectively, in comparison to the 
LV-enhanced green fluorescent protein (eGFP) transduced con-
trol cells (Supplementary Figure S1b,d). As expected, this led to 
increased enzyme diffusion (ninefold and twofold for the K562 
and Fabry B cells, respectively) (Supplementary Figure S1b,d). 
Next, we transduced normal human mobilized PB CD34+ cells 
(Figure 3a) at a multiplicity of infection of 15 and evaluated out-
comes in vitro. Four days after lentiviral infection, flow cytometry 
analyses revealed that on average, 51 ± 14% and 36 ± 10% (n = 3) 
of the human progenitor cells were positive for expression of the 
downstream selectable marker originating from our bicistronic 
LV construct or from LV-eGFP, respectively (Figure 3b). Similar 
results obtained 14 days after transduction demonstrate the stable 
nature of the transgenes (data not shown). Clonogenic studies 
(Figure 3c) showed no differences in the total number of colonies 
nor in the percentage of the different lineages among the groups 
(LV-α-gal A/IRES/hCD25 versus LV-eGFP or nontransduced 
control cells). PCR analysis18 showed the expected proportion 
of vector-positive colonies (nontransduced cells: 0/90, LV-eGFP: 
28/92, and LV-α-gal A/IRES/hCD25: 46/96). Moreover, by using 
the LV-α-gal A/IRES/hCD25 vector, the α-gal A activity of the 
enzymatically normal CD34+ cells was increased more than two-
fold in comparison to the nontransduced or LV-eGFP transduced 
control cells (Figure 3d). Taken together, these data suggest that 
the gross physiology of the HSCs was not affected by the lentiviral 
infection or by transgene expression in this case.
Human cell engraftment into nsF mice
Next, we performed two independent transplantations using normal 
human HSCs into separate NSF mice cohorts as described below. 
Cells were injected intravenously into 8-week-old male NSF mice 
(8 × 105 cells/mouse, 6–10 mice/group/experiment). Engraftment 
of the human hematopoietic cells was regularly evaluated (4, 6, 8, 
10, and 12 weeks after transplantation) by determining the percent-
age of hCD45+ cells in the PB of recipient mice (Figure 4a). As 
shown in Figure 4b, at 4 weeks after transplant, ~2% of the total 
white blood cells were derived from the injected human HSCs (for 
both experimental groups LV-eGFP and LV-α-gal A/IRES/hCD25). 
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Figure 2 lentivector schema. Schema of the lentivectors used in the 
present study. Control vector, LV-eGFP, and therapeutic vector, LV-α-
gal A/IRES/hCD25. α-gal A, α-galactosidase A; cPPT, central polypurine 
tract; EF1-α, elongation factor 1-α promoter; eGFP, enhanced green 
fluorescent protein; IRES, internal ribosome entry site; LTR, long terminal 
repeat; RRE, Rev responsive element; SA, 3′ splice acceptor site; SD, 5′ 
splice donor site; SIN, self-inactivating LTR; WPRE, woodchuck hepatitis 
virus post-transcriptional regulatory element; ψ, human immunodefi-
ciency virus packaging signal.
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Figure 3 Phenotypic characterization of lV-transduced human cd34+ progenitor cells. (a) Representative flow cytometry analysis of the normal 
human CD34+ cells used in the in vivo experiment. (b) Percentage of eGFP or hCD25+ cells at 4 days after transduction of the progenitor cells. A rep-
resentative flow cytometry analysis is shown. (c) Representative clonogenic assay evaluated at 14 days after transduction. (d) Progenitor enzymatic 
activity evaluated 14 days after transduction. Data are mean ± SD (n = 3). *P < 0.01 compared to NT or LV-eGFP control cells. α-gal A, α-galactosidase 
A; BFU-E, burst-forming unit-erythroid; CFU-GM, colony-forming unit-granulocyte and macrophage; CFU-GEMM, colony-forming unit-granulocyte, 
erythrocyte, macrophage, and megakaryocyte; eGFP, enhanced green fluorescent protein; FSC-H, forward scatter; IRES, internal ribosome entry site; 
LV, lentiviral vector; NT, nontransduced cells.
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Figure 4 High level of engraftment of human Hscs in nod/scId/Fabry mice. Transduced progenitor cells (8 × 105) were injected intravenously 
into sublethally irradiated NOD/SCID/Fabry mice. (a) Representative flow cytometry analysis of the percentage of hCD45+ cells in peripheral blood at 
different time points. (b) Percentage of hCD45+ cells in peripheral blood analyzed by flow cytometry at different time points. (c) Representative flow 
cytometry analysis for LV-eGFP positive cells in circulation. (d) Representative dot-plot analysis of human cell engraftment from bone marrow samples 
12 weeks after transplantation. (e) Bone marrow engraftment of human cells in all mice evaluated 12 weeks after transplant. (f) Representative 
hCD45+/eGFP+ cell engraftment analysis from pooled bone marrow samples. (g) Percentage of hCD34+/eGFP+ cells in bone marrow pools. Each 
open circle or black square represents an individual mouse. Two independent experiments were performed. α-gal A, α-galactosidase A; APC, allophy-
cocyanin; eGFP, enhanced green fluorescent protein; FSC-H, forward scatter; HSC, hematopoietic stem cells; IRES, internal ribosome entry site; LV, 
lentiviral vector; NOD, nonobese diabetic; NSF, NOD/SCID/Fabry; NS, NOD/SCID; SCID, severe combined immunodeficiency; SSC-H, side scatter.
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The percentage of hCD45+ cells rapidly increased reaching a maxi-
mum at 8 weeks after infusions (Figure 4b) before declining again 
by the 10th week. It is worthwhile to mention that no differences 
in engraftment were observed between the groups at any of the 
evaluated times. Moreover, the presence of LV-eGFP positive cells 
in circulation demonstrated that this new model allows not only 
the engraftment of modified human cells but also their proliferation 
and differentiation (Figure 4c). Similar flow cytometry engraftment 
analyses were performed on bone marrow cells at euthanization (12 
weeks after transplantation). As denoted in Figure 4d,e, a high per-
centage of hCD45+ cells was observed in the bone marrow of the 
transplanted mice (30 ± 21% and 32 ± 20% for the LV-eGFP and 
LV-α-gal A/IRES/hCD25 groups, respectively) demonstrating no 
differences in the level of chimerism between both experimental 
groups. The feasibility of engraftment of the modified cells was con-
firmed by the presence of eGFP positive cells in the bone marrow 
(Figure 4f) of the transplanted mice. One interesting point is that 
~30% of the hCD34+ cells found in the bone marrow expressed the 
control transgene showing that multipotent human hematopoietic 
cells had been transduced (Figure 4g). Furthermore, no differences 
were observed in multilineage progenitor cell analyses performed 
on the bone marrow pools (hCD45+ cells: ~31 ± 9%; hCD19+ cells: 
~25 ± 6%, and hCD33+cells: ~6 ± 3%).
α-Gal A activity augmentation along with significant 
organ Gb3 reductions in lV-α-gal A/Ires/hcd25 
transplanted mice
To evaluate the outcome of the LV-mediated gene therapy 
approach in this novel xenograft model, we first analyzed the 
plasma α-gal A activity after transplantation. Even though no 
hCD25+ cells were detectable in circulation (data not shown), the 
α-gal A activity in the plasma was significantly increased at all the 
evaluated time points (Figure 5a). Although the LV-eGFP group 
exhibited enzyme activity that was similar to pretransplantation 
levels, the LV-α-gal A/IRES/hCD25 experimental group showed 
an increase in plasma α-gal A activity of up to 20% (Figure 5a). As 
expected, a significant increase in the α-gal A enzyme activity was 
observed in the bone marrow cells, spleen, and liver of the LV-α-
gal A/IRES/hCD25 group at 12 weeks after infusion (Figure 5b). 
At killing, organs were harvested from transplanted animals and 
the Gb3 content was measured by detailed high-performance liq-
uid chromatography analyses. As shown in Figure 5c, liver, lung, 
and spleen showed a significant decrease in Gb3 content prompted 
by the infusion of normal cells (LV-eGFP versus nontransplanted 
NSF mice). In contrast, key organs in the pathophysiology of 
Fabry disease, specifically the heart and kidneys, did not benefit 
by the infusion of the control-transduced normal human CD34+ 
cells (LV-eGFP group). Importantly however, Gb3 content in these 
key organs, as well as liver, lung, and spleen, was significantly 
reduced in mice transplanted with the LV-α-gal A/IRES/hCD25-
therapeutically modified cells (Figure 5c). This demonstrates that 
LV-mediated transduction has the capacity to mediate broader 
systemic correction through metabolic cooperativity.
In order to begin to explain the differences in Gb3 reduction in 
tissues among both transplanted cohorts, in another experiment 
we infused 2.5 × 106 engineered-hCD34+ cells (~20% LV-eGFP 
positive cells) into NSF mice and analyzed the tissue distribution 
of these modified human cells 8 weeks after transplant. As shown 
in Figure 5d, PB, bone marrow, and spleens of these mice harbored 
LV-eGFP–transduced cells that correlated well with the augmen-
tation of α-gal A enzyme observed in such tissues (Figure 5a,b). 
Similar results were obtained by immunostaining for the eGFP 
protein; while heart and kidney were negative (data not shown). 
These data suggest that there is localized enzyme production in the 
organs and that the bone marrow and spleen are major contribu-
tors that secrete enzyme into the circulation, elevating systemic 
α-gal A levels. Interestingly, rare eGFP positive cells were found 
in the brain of the transplanted mice (data not shown) suggest-
ing that a gene therapy approach may have advantages over ERT, 
for example, for correcting the cerebrovascular manifestations of 
Fabry disease. Lastly, it is worth noting that in this experiment the 
genetic modification of long-term progenitor cells did not affect 
their normal differentiation into hCD3+, hCD19+, hCD33+, and 
hCD14+ cells, and that the transgene was equally expressed in all 
the lineages (Figure 5d).
dIscussIon
In this study, we have generated a novel NSF mouse model that 
accepts xenogeneic HSC transplantation. Moreover, by using this 
model we demonstrated that genetically modified bone marrow 
cell transplantation improves outcomes, as measured by Gb3 accu-
mulation, over HSC transplantation alone. While the generation 
of a Fabry mouse17 represented a milestone for the field, we sought 
a more directly translational model that allows us to work with 
human cells and evaluate the consequences of therapeutic inter-
vention. This novel model also facilitates our collection of key 
preclinical data for future implementation of a gene therapy trial 
for Fabry disease as toxicity and efficiency measurements can be 
made on the true target population in an in vivo setting.
We generated this fully congenic xenograft model by changing 
the genetic background of the pre-existent Fabry mouse through 
eleven generations of backcrossings. Our NSF mice exhibited a defi-
ciency of α-gal A activity and progressive Gb3 accumulation, but 
also did not mimic the clinical symptoms of Fabry disease. Studies 
performed in a previous Fabry mouse model revealed that the 
murine erythrocytes, a likely source of Gb3 in humans, do not con-
tain appreciable level of Gb4 (Gb3 precursor) or even Gb3 itself sug-
gesting that the lipid accumulation in mice would be milder than in 
humans.19 However, considering that by thin layer chromatography 
lipid analysis we were able to observe small amounts of Gb4 as well 
as Gb3 accumulation in packed NSF erythrocytes (data not shown), 
this earlier explanation may not be directly translatable to our cur-
rent model. In this regard, more studies have to be performed in 
order to elucidate the mechanisms that make this murine model 
less susceptible to typical Fabry disease manifestations.
Some clinical studies have recognized that the best outcomes 
may be achieved by increasing the frequency of administration 
of α-gal A, suggesting that cells/tissues may require a continuous 
presence of the enzyme.20,21 It has been previously postulated that 
only 15–20% of the normal α-gal A activity is sufficient to medi-
ate significant clinical improvements.22 We have shown that this 
level of efficiency is feasible and that a long-term, and continu-
ous production of enzyme can be achieved through the lentiviral 
infection of bone marrow cells followed by transplantation.23 In our 
© The American Society of Gene & Cell Therapy
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experiments, we did not observe significant Gb3 reduction in the 
heart and kidneys of the control transplanted mice. Consequently, 
we propose that allogeneic bone marrow transplantation, as repre-
sented by the LV-eGFP control group, may be insufficient to medi-
ate treatment in these organs, meaning that the amount of enzyme 
that was secreted by normal cells was not enough to reach thera-
peutic levels in circulation. Moreover, the significant lipid reduction 
observed in liver, lung, and spleen of the eGFP mice group may be, 
in essence, a localized effect. It has been described that in NOD/
SCID transplanted mice most of the human progenitor cells usually 
engraft in the bone marrow, spleen, and liver.24–26 Our data are con-
sistent with those findings as we showed a significant increase in 
the α-gal A activity in those same organs. We also showed increases 
in α-gal A activity in the plasma of the therapeutically transplanted 
group, reaffirming not only the improved therapeutic outcomes of 
the LV-α-gal A/IRES/hCD25 transduced cohort in such localized 
tissues, but that potent cross-correction effects likely mediate cor-
rection of the hearts and kidneys of the experimental group.
LV-modified autologous cells offer several advantages in com-
parison to allogeneic bone marrow transplantation for treatment 
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Figure 5 α-Gal A activity augmentation and organ Gb3 reduction in the lV-α-gal A/Ires/hcd25 transplanted mice. (a) Plasma α-gal A enzyme 
activity was evaluated at 4, 6, 8, 10, and 12 weeks after transplantation. Data were normalized to nontransplanted NOD/SCID/Fabry mice enzyme levels 
and represent mean ± SEM (n = 16). *P < 0.05, **P < 0.01, and ***P < 0.001 compared to the LV-eGFP control group. (b) Bone marrow, spleen, and liver 
α-gal A enzyme activity at killing. Data represent mean ± SEM (n = 16). *P < 0.01 compared to nontransplanted group and #P < 0.05 versus eGFP group. 
(c) HPLC-based Gb3 quantification in heart, kidney, liver, lung, and spleen at 12 weeks after transplantation. Data represent mean ± SEM (n = 16). *P < 
0.01 compared to nontransplanted group and &P < 0.01 or #P < 0.05 versus the LV-eGFP group. (d) Representative flow cytometry analyses of engineered 
cell tissue engraftment. α-gal A, α-galactosidase A; eGFP, enhanced green fluorescent protein; Gb3, globotriaosylceramide; IRES, internal ribosome entry 
site; LV, lentiviral vector; NOD, nonobese diabetic; NSF, NOD/SCID/Fabry; NS, NOD/SCID; SCID, severe combined immunodeficiency.
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of lysosomal storage disorders. First, the use of autologous cells 
would reduce the morbidity and mortality associated with the 
procedure. Second, the risks of graft-versus-host disease would 
be abolished. Lastly, as we have shown here, engineered cells can 
express much higher levels of the therapeutic enzyme, rendering 
them more effective than transplanted wild-type cells. In spite 
of being unable to detect the expression of the hCD25 selectable 
marker at appreciable levels (less than 1%, data not shown) in the 
PB, the increase in the α-gal A activity was clearly noted in the 
plasma, spleen, liver, and bone marrow cell samples. This lower 
marker expression could be related to the activation of different 
clones in the bone marrow resulting in an in vivo hCD25+ cell 
dilution or a lower expression of the second transgene compared 
to the first one (the α-gal A gene in this case). Indeed, it has been 
previously demonstrated that in a bicistronic construct with an 
IRES element, the efficiency of expression of the second gene is 
usually lower than the first one, with the expression level varying 
from 6 to 100% (relative to first gene expression), depending on 
cell types and reporter genes.27 Enzyme-secreting cells could have 
also engrafted in regions not sampled by PB analyses.
In summary, these results show that our novel NSF mouse 
model exhibits a deficiency in α-gal A activity with typical Gb3 
accumulation as observed in Fabry disease, but also can accept 
transplanted human CD34+ cells. Gb3 accumulation in this novel 
xenograft model was partially corrected by infusion of normal 
human CD34+ cells. However, the greatest benefits were medi-
ated by infusion of genetically modified CD34+ cells. These results 
support the idea that allogeneic bone marrow transplantation 
by itself is not sufficient to achieve adequate levels of metabolic 
cooperativity and suggest gene therapy as a focus for correction of 
Fabry disease and other lysosomal storage disorders.
MAterIAl And MetHods
Development of the NSF mouse. α-Gal A-deficient Fabry mice17 were 
bred at the Animal Resource Center, University Health Network (UHN). 
NOD.CB17-Prkdcscid (NOD/SCID) mice were purchased from Jackson 
Laboratories (Bar Harbor, ME) and bred in a colony maintained at UHN. 
Animal experimentation protocols were approved by the UHN Animal 
Care Committee. The parental generation (F0) consisted of Fabry female 
(α-gal A−/−scid+/+) and NOD/SCID male (α-gal A+/0scid−/−) mice. F1-double 
heterozygous female mice (α-gal A+/−scid+/−) were mated with NOD/SCID 
male mice to generate α-gal A+/−scid−/− female mice (F2). For all the back-
crosses, the NSF-offspring genotype was analyzed from tail DNA following 
Jackson Laboratories and Ohshima et al.19 conditions, respectively. Nine 
additional generations (F3–F11) were prepared by backcrossing heterozy-
gous Fabry females (α-gal A+/−scid−/−) with NOD/SCID males. The F11-
genetic background was determined by NOD/SCID genomic scanning 
(225 single-nucleotide polymorphisms were analyzed) at the Jackson 
Laboratories. Mice harboring >99% NOD/SCID genetic background were 
selected and interbred to obtain the double homozygous female mice (F12). 
The pure NSF line (F13) was finally achieved by breeding the homozygous 
Fabry female mice (F12) with the hemizygous male mice (F12). The NSF 
phenotype was also confirmed by determining the absence of mature T 
and B cells by flow cytometry, assessment of the specific α-gal A enzyme 
activity, and evaluation of organ Gb3 accumulation by high- performance 
liquid chromatography (see below). Fabry mice17 and NOD/SCID mice (as 
above) were also used as controls.
α-Gal A activity assay and Gb3 quantification. The specific α-gal A 
activity was determined by fluorometric assay as previously described.16 
Briefly, plasma or cells/organs protein extracts were incubated with 
4-methylumbelliferyl-α-D-galactopyranoside (5 mmol/l) (RPI, Mount 
Prospect, IL) in presence of the α-N-acetylgalactosaminidase inhibi-
tor, N-acetyl-D-galactosamine (100 mmol/l) (Sigma, Oakville, Ontario, 
Canada). The product of the enzymatic reaction was quantified by com-
parison with known concentrations of 4-methylumbelliferone. Mouse 
organ Gb3 content was determined by high-performance liquid chroma-
tography as described.19 Each measurement was assessed in triplicate, and 
normalized to total protein concentration (DCT Protein Assay; Bio-Rad 
Laboratories, Mississauga, Ontario, Canada).
Vectors and lentivirus production. The LV pHR′cPPT-EF1α-α-gal 
A-IRES-hCD25-WPRE-SIN (LV-α-gal A/IRES/hCD25) was previously 
constructed in our lab.16 Vesicular stomatitis virus glycoprotein-pseu-
doptyped lentiviruses (VSVg-LVs), including an eGFP control vector 
(LV-eGFP), were generated as described23 by cotransfection of the LV 
plasmid construct (LV-eGFP or LV-α-gal A/IRES/hCD25) in combination 
with the packaging (pCMVΔR8.91) and VSVg envelope-coding (pMD.G) 
plasmids into HEK 293T cells. Viral supernatants were harvested 48 hours 
later and concentrated by ultracentrifugation at 50,000g for 2 hours. Viral 
stocks were resuspended in phosphate-buffered saline containing bovine 
serum albumin (1% wt/vol) and stored at −80 °C until use. LV suspensions 
were serially diluted and functionally titered on HEK 293T cells by analyz-
ing the transgene expression by flow cytometry. Titers of each of the LV 
preparations were higher than 1 × 109 functional infectious particles/ml as 
measured by eGFP and hCD25 expression analyses (data not shown).
Cell transduction and transplantation protocol. K562 (human erythro-
leukemic cells) cells and Fabry patient B cells12 were cultured in RPMI-
1640 media (Sigma) supplemented with 10% fetal bovine serum (PAA, 
Toronto, Ontario, Canada), 2 mmol/l glutamine, 100 U/ml penicillin, and 
100 mg/ml streptomycin (all from Invitrogen, Carlsbad, CA) and main-
tained in a humidified incubator at 37 °C in an atmosphere containing 
5% CO2. Human mobilized PB CD34
+
 cells were obtained from AllCells 
(Emeryville, CA). These cells were rapidly thawed following the manufac-
turer’s recommendations. After thawing, ~85% of the cells were viable as 
assessed by trypan blue exclusion, while the hCD34 expression was higher 
than 90% as determined by flow cytometry analysis. Cells were prestim-
ulated for 24 h in StemSpan media (Stemcell Technologies, Vancouver, 
British Columbia, Canada) supplemented with SCF (100 ng/ml), Flt-3 
(50 ng/ml), TPO (50 ng/ml), and IL-6 (20 ng/ml) (all from R&D System, 
Minneapolis, MN). Cells were then resuspended in concentrated LV 
supernatants (LV-eGFP or LV-α-gal A/IRES/hCD25) at a concentration of 
1 × 106 cells/ml and cultured overnight on Fibronectin (5 μg/cm2; Sigma) 
coated plates. Vector supernatants were added at a functional multiplic-
ity of infection of 15 and supplemented with the aforementioned cytokine 
cocktail plus 8 mg/ml protamine sulfate (Sigma). Flow cytometry analysis 
was performed 72 hours later to examine eGFP or hCD25 expression on 
mobilized PB CD34
+
 cells. Clonogenic assays were also performed follow-
ing manufacturer’s recommendations (Stemcell Technologies) while the 
assessment of vector-positive cells was analyzed as described.18
Recipient mice were sublethally irradiated (300cGy) and injected 
intraperitoneally with 200 μg of purified anti-CD122 antibody 24 hours 
before transplantation for natural killer cell depletion as described.28 
Vector transduced cells (8 × 105/mouse) were injected into the tail vein of 
8-week-old NSF male mice. Age- and sex-matched NSF and NOD/SCID 
mice were used as untouched or wild-type controls, respectively. Mice 
were analyzed up to 12 weeks after transplantation.
Flow cytometry analysis. Single-cell suspensions of PB and bone marrow 
were generated following collection from mice at the time of analysis. Red 
blood cells were lysed in ammonium chloride (150 mmol/l), potassium 
bicarbonate (10 mmol/l), and ethylenediaminetetraacetic acid (0.1 mmol/l) 
for 5 minutes at 37 °C (all from Sigma). Cells were washed with phosphate-
buffered saline and resuspended in FACS buffer (phosphate-buffered 
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saline, 0.5% fetal bovine serum, and 2 mmol/l ethylenediaminetetraacetic 
acid) on ice and stained with the appropriate antibody. The following 
antibodies were used: hCD25-PE, hCD45-APC, hCD45-PE, hCD34-PE, 
hCD19-PE, hCD33-PE, hCD14. All antibodies were obtained from BD 
Biosciences (Mississauga, Ontario, Canada). Cells were then analyzed by 
flow cytometry using a FACSCalibur (BD) and data were analyzed using 
CellQuestPro software (BD).
Statistical analysis. Results are expressed as mean ± SD or SEM as indicated 
and are representative of two independent experiments with 6–10 animals 
per group. Differences between groups were assessed using Student’s t-test 
or analysis of variance. Values of P < 0.05 were considered to be statistically 
significant.
suPPleMentArY MAterIAl
Figure S1. High intracellular levels of α-gal A activity and secretion 
in vitro mediated by therapeutic LV transduction.
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